Details

Autor(en) / Beteiligte

• Aldoss, Ibrahim
• La Rosa, Corinna
• Baden, Lindsey R
• Longmate, Jeffrey
• Ariza-Heredia, Ella J
• Rida, Wasima N
• Lingaraju, Chetan Raj
• Zhou, Qiao
• Martinez, Joy
• Kaltcheva, Teodora
• Dagis, Andy
• Hardwick, Nicola
• Issa, Nicolas C
• Farol, Len
• Nademanee, Auayporn
• Al Malki, Monzr M
• Forman, Stephen
• Nakamura, Ryotaro
• Diamond, Don J

Titel

Poxvirus Vectored Cytomegalovirus Vaccine to Prevent Cytomegalovirus Viremia in Transplant Recipients: A Phase 2, Randomized Clinical Trial

Ist Teil von

• Annals of internal medicine, 2020-03, Vol.172 (5), p.306

Ort / Verlag

United States

Erscheinungsjahr

2020

Quelle

MEDLINE

Beschreibungen/Notizen

• Triplex vaccine was developed to enhance cytomegalovirus (CMV)-specific T cells and prevent CMV reactivation early after hematopoietic stem cell transplant (HCT). To determine the safety and efficacy of Triplex. First-in-patient, phase 2 trial. (ClinicalTrials.gov: NCT02506933). 3 U.S. HCT centers. 102 CMV-seropositive HCT recipients at high risk for CMV reactivation. Intramuscular injections of Triplex or placebo were given on days 28 and 56 after HCT. Triplex is a recombinant attenuated poxvirus (modified vaccinia Ankara) expressing immunodominant CMV antigens. The primary outcomes were CMV events (CMV DNA level ≥1250 IU/mL, CMV viremia requiring antiviral treatment, or end-organ disease), nonrelapse mortality, and severe (grade 3 or 4) graft-versus-host disease (GVHD), all evaluated through 100 days after HCT, and grade 3 or 4 adverse events (AEs) within 2 weeks after vaccination that were probably or definitely attributable to injection. A total of 102 patients (51 per group) received the first vaccination, and 91 (89.2%) received both vaccinations (46 Triplex and 45 placebo). Reactivation of CMV occurred in 5 Triplex (9.8%) and 10 placebo (19.6%) recipients (hazard ratio, 0.46 [95% CI, 0.16 to 1.4]; P = 0.075). No Triplex recipient died of nonrelapse causes during the first 100 days or had serious AEs, and no grade 3 or 4 AEs related to vaccination were observed within 2 weeks after vaccination. Incidence of severe acute GVHD after injection was similar between groups (hazard ratio, 1.1 [CI, 0.53 to 2.4]; P = 0.23). Levels of long-lasting, pp65-specific T cells with effector memory phenotype were significantly higher in Triplex than placebo recipients. The lower-than-expected incidence of CMV events in the placebo group reduced the power of the trial. No vaccine-associated safety concerns were identified. Triplex elicited and amplified CMV-specific immune responses, and fewer Triplex-vaccinated patients had CMV viremia. National Cancer Institute and Helocyte.